Anal Cancer Study-EA2176

EA2176: A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients.

 

The purpose of the EA2176 study is to compare chemotherapy alone (this is the standard treatment for metastatic anal cancer) to chemotherapy plus immunotherapy (nivolumab). Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. This study will help the study doctors find out if chemotherapy plus immunotherapy helps reduce symptoms and stop your cancer from growing.

Principal Investigator

Massey Cancer Center
Matin, Khalid 

Contact

Riverside Cancer Clinical Team
757-534-6890
[email protected]

Locations

All Peninsula Cancer Institute and Cancer Specialists of Tidewater sites

Status

Recruiting

Category

Oncology

Study #

NCT04444921